Investigation of Vasodilation and Intensity of Headache Triggered by Glucagon Like Peptide-1 in Humans
Investigation of Vasodilation and Intensity of Headache Triggered by Glucagon-like Peptide-1 in Healthy Volunteers and Migraine Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Hashmat Ghanizada, MD
- Phone Number: 38633470
- Email: hashmat.ghanizada@regionh.dk
Study Locations
-
-
-
Glostrup, Denmark, 2600
- Recruiting
- Dansk Hovedpinecenter
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Criteria for the healthy volunteers group
Inclusion Criteria:
- Healthy men/women.
- Age 18 to 60 years old.
- Weight 50 to 100 kg.
Exclusion Criteria:
- Tension headache more than 5 days a month in the preceding year.
- All other primary headache types.
- Headache on the examination day or within 48 hours before infusion of the study drug.
- Smoking.
- Daily intake of medicine of any kind except for peroral contraceptives.
- Women, who on the day of examination is 2 days before or 3 days from the first day of bleeding.
- Hypertension or hypotension.
- Coronary heart disease of any kind, as well as cerebrovascular disease.
- Pulmonary disease.
- Allergy to contents in the study drug.
- Psychiatric disease or substance abuse.
- Disease of any kind which the examining doctor deems relevant for participation in the study.
- Renouncing the right to information concerning own health.
Criteria for the migraine patients group
Inclusion Criteria:
- Migraine patients, who fulfill the ICHD-3 criteria for migraine without aura.
- Age 18 to 60 years old.
- Weight 50 to 100 kg.
Exclusion Criteria:
- Tension headache more than 5 days a month in the preceding year.
- All other primary headache types.
- Headache on the examination day or within 48 hours before infusion of the study drug.
- Smoking.
- Daily intake of medicine of any kind except for peroral contraceptives.
- Women, who on the day of examination is 2 days before or 3 days from the first day of bleeding.
- Hypertension or hypotension.
- Coronary heart disease of any kind, as well as cerebrovascular disease.
- Pulmonary disease.
- Allergy to contents in the study drug.
- Psychiatric disease or substance abuse.
- Disease of any kind which the examining doctor deems relevant for participation in the study.
- Renouncing the right to information concerning own health.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: GLP-1
Receive intravenous infusion of GLP-1.
|
Receive intravenous infusion of GLP-1.
The dosage will be determined after a dose finding pilot study.
|
|
Placebo Comparator: Placebo
Receive intravenous infusion of saline.
|
Receive intravenous infusion saline
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vasodilation
Time Frame: 120 minutes
|
Difference in circumference (in millimeter) of intra - and extracranial blood vessels before and after GLP-1 or placebo infusion, measured by transcranial doppler and ultrasound (Derma scan) at 10 specific time points (-10, 10, 20, 30, 40, 50, 60, 80, 100, and 120 minutes)
|
120 minutes
|
|
Headache intensity
Time Frame: 12 hours
|
Headache intensity will be measured using Numerical rating scale (NRS) from ( 0 to 10 )
|
12 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
blood pressure
Time Frame: 120 minutes
|
Blood pressure (systolic and diastolic) in mmhg will be measured every 10 minutes
|
120 minutes
|
|
Facial skin perfusion
Time Frame: 120 minutes
|
Non-invasive measuring of facial skin perfusion by laser speckle contrast imager.
|
120 minutes
|
|
Heart rate
Time Frame: 120 minutes
|
heart rate will be measured every 10 minutes
|
120 minutes
|
|
Plasma glucose
Time Frame: 120 minutes
|
Plasma glucose will be measured using (mmol/L) a ABL Radiometer, Denmark Blood-gas analyser
|
120 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- H-19037051
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.